The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy

Background. This study was performed to evaluate the use of the 1992 International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) T categories for localized prostate cancer treated with radiation therapy and to compare the prognostic power of this system with the Whitmore‐Jewett scheme.

[1]  G. Zagars.  Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. , 1993, The Urologic clinics of North America.

[2]  A. V. von Eschenbach,et al.  Prognostic factors in prostate cancer: Analysis of 874 patients treated with radiation therapy , 1993 .

[3]  A. V. von Eschenbach,et al.  Prostate‐specific antigen. An important marker for prostate cancer treated by external beam radiation therapy , 1993, Cancer.

[4]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[5]  Galina Pizov,et al.  Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.

[6]  D. Bostwick,et al.  Staging of early prostate cancer: a proposed tumor volume-based prognostic index. , 1993, Urology.

[7]  J. Oesterling,et al.  Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. , 1993, Urology.

[8]  E. Bergstralh,et al.  Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. , 1993, Urology.

[9]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[10]  T. Stamey,et al.  The predictive significance of substaging stage A prostate cancer (A1 versus A2) for volume and grade of total cancer in the prostate. , 1992, The Journal of urology.

[11]  P. Scardino,et al.  The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. , 1991, The Journal of urology.

[12]  R. Babaian,et al.  Prostate‐Specific Antigen and External Beam Radiation Therapy in Prostate Cancer , 1991, Cancer.

[13]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[14]  E. K. Harris,et al.  Survivorship Analysis for Clinical Studies , 1990 .

[15]  C. Gatsonis,et al.  Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. , 1990, The New England journal of medicine.

[16]  W. Catalona,et al.  New staging systems for prostate cancer. , 1989, The Journal of urology.

[17]  C. Perez,et al.  Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  R. Cox,et al.  Status of radiation treatment of prostate cancer at Stanford University. , 1989, NCI monographs : a publication of the National Cancer Institute.

[19]  A. V. von Eschenbach,et al.  The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate. , 1988, International journal of radiation oncology, biology, physics.

[20]  P. Schellhammer.  Radical prostatectomy. Patterns of local failure and survival in 67 patients. , 1988, Urology.

[21]  A. V. von Eschenbach,et al.  Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation , 1987, Cancer.

[22]  P. Walsh,et al.  Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. , 1986, The Journal of urology.

[23]  J. Smith,et al.  Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma. , 1986, The Journal of urology.

[24]  D E Johnson,et al.  Histologic grading study of prostate adenocarcinoma: The development of a new system and comparison with other methods—A preliminary study , 1982, Cancer.

[25]  P. Walsh,et al.  Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. , 1981, The Journal of urology.

[26]  P. Walsh,et al.  Radical Surgery for Prostatic Cancer , 1980, Cancer.

[27]  P. Morales,et al.  Stage A2 prostatic carcinoma: should staging system be reclassified? , 1979, Urology.

[28]  R. Schinella,et al.  Differences in pathological characteristics and prognosis of clinical A2 prostatic cancer from A1 and B disease. , 1978, The Journal of urology.

[29]  D. Hussey,et al.  Megavoltage radiation therapy for carcinoma of the prostate. , 1977, International journal of radiation oncology, biology, physics.

[30]  Jewett Hj.  The present status of radical prostatectomy for stages A and B prostatic cancer. , 1975 .

[31]  J. Herman.  Hawes orchitis compressor. , 1974, Urology.

[32]  W. Whitmore.  Hormone therapy in prostatic cancer. , 1956, The American journal of medicine.

[33]  J. Oesterling,et al.  Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. , 1993, Urology.

[34]  G. Zagars.  Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. , 1992, International journal of radiation oncology, biology, physics.

[35]  F. Schröder,et al.  The TNM classification of prostate cancer , 1992, The Prostate. Supplement.

[36]  T. Stamey,et al.  Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. , 1988, The Journal of urology.